Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:54 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
DOAC Versus VKA After Cardiac Surgery
NCT04002011 · Laval University · PHASE2 · withdrawn · last registry update 2023-03-13 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Submission process abandoned. No patient enrolled.” | – | Registry record, Laval University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against VKORC1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-01-29Results posted on the registry: Eli Lilly and Company, Drug Cocktail + Mirikizumab (NCT03718884)
- 2023-12-20Results posted on the registry: The Medicines Company, Oritavancin + Warfarin (NCT02452918)
- 2023-10-03Results posted on the registry: Alliance Foundation Trials, LLC., Rivaroxaban + Apixaban (NCT02744092)
- 2023-09-21Phase 3 first posted: University Hospital, Caen, Anticoagulation Agents (NCT06045858)
- 2023-07-17Results posted on the registry: Boehringer Ingelheim, Percoffedrinol® + Coumadin® (NCT04679948)
- 2023-07-11Results posted on the registry: HealthPartners Institute, 4-factor prothrombin complex concentrate (4FPCC) (NCT03064035)
- 2023-06-29Results posted on the registry: University of Michigan, a drug against VKORC1 (NCT05085405)
- 2023-04-24Phase 3 first posted: Pulnovo Medical (Wuxi) Co., Ltd., Guideline-directed medical therapy (GDMT) for heart failure (NCT05824923)
- 2023-04-24Phase 3 first posted: Centre Hospitalier Universitaire de Nīmes, Vitamin K antagonist + Direct oral anticoagulant (NCT05825573)
- 2023-03-06Results posted on the registry: Daiichi Sankyo, Edoxaban + Standard of Care (NCT02798471)
- 2023-01-30Phase 3 first posted: Rajaie Cardiovascular Medical and Research Center, Rivaroxaban 15 MG + Warfarin (NCT05705089)
- 2022-10-18Results posted on the registry: Eli Lilly and Company, Drug Cocktail + Abemaciclib (NCT02688088)
- 2022-08-25Phase 3 first posted: Instituto Mexicano del Seguro Social, Rivaroxaban 20 MG [Xarelto] + Aspirin 300mg (NCT05515120)
- 2022-07-26Results posted on the registry: Daiichi Sankyo, Edoxaban + Standard of Care (SOC) (NCT03395639)
- 2022-05-18Results posted on the registry: Bristol-Myers Squibb, Apixaban + Vitamin K Antagonist (VKA) (NCT02981472)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision